Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Alliance / A092001

Trial Overview

Official Title

PHASE 2 RANDOMIZED TRIAL OF NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY FOR PERITONEAL MESOTHELIOMA

Study Purpose

To determine whether frontline treatment with carboplatin, pemetrexed, bevacizumab and atezolizumab results in a superior best response rate than carboplatin, pemetrexed and bevacizumab in patients with peritoneal mesothelioma

Diagnosis

Peritoneal mesothelioma

Eligibility

Must be over age of 18

Must be willing to sign consent and agree to study procedures

Must meet all study criteria for eligibility (testing would be completed after a patient signs consent for study)

Diagnosis of peritoneal mesothelioma

No prior treatment for disease

Intervention

Eligible patients are randomized (similar to flip of a coin) to receive either of two drug combinations:  Carboplatin, Pemetrexed, Bevacizumab, Atezolizumab or Carboplatin, Pemetrexed, Bevacizumab

 

After four cycles, patients are re-evaluated for response to treatment and may be offered surgical intervention or additional therapy

For more information, click the link below:

 

https://clinicaltrials.gov/study/NCT05001880?term=A092001&rank=1

 

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center Methodist Jennie Edmundson Hospital
Gender
Male or Female
Age
19 years of age or older
Enrollment Status
Available
Phase
Phase II
Methodist Health System Trial Code
A092001